ROOT, Switzerland - Novocure (NASDAQ: NVCR), a $2.17 billion medical technology company whose stock has surged over 34% year-to-date according to InvestingPro, has announced that its Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The trial tested the efficacy of Tumor Treating Fields (TTFields) therapy used alongside chemotherapy agents gemcitabine and nab-paclitaxel.
Patients who received TTFields therapy in combination with the chemotherapy had a median overall survival of 16.20 months, compared to 14.16 months for those who received chemotherapy alone. This marked a 2.0-month improvement, with the survival rate benefit increasing over time—13% at 12 months and 33% at 24 months.
Vincent Picozzi, M.D., a medical oncologist and investigator in the PANOVA-3 trial, remarked on the promising data, especially for a patient population that is difficult to treat. The trial enrolled 571 patients who were followed for at least 18 months.
Novocure's Chief Medical (TASE:PMCN) Officer, Nicolas Leupin, M.D., Ph.D., expressed gratitude to the patients and investigators and indicated that the full trial results would be presented at an upcoming medical congress. The company plans to seek regulatory approval for TTFields in the treatment of unresectable, locally advanced pancreatic adenocarcinoma in the U.S., EU, Japan, and other key markets.
TTFields therapy involves the use of electric fields designed to disrupt cancer cell division, which has been shown to have a multimechanistic effect on tumor cells. This therapy is already approved for certain cancers and is being explored further in ongoing and completed clinical trials for various types of cancer. The company maintains impressive gross profit margins of 76.5% and has achieved revenue growth of 14.6% over the last twelve months, according to InvestingPro data.
Pancreatic cancer remains one of the most lethal forms of cancer, with increasing incidence and death rates. The five-year relative survival rate is only 13%, underscoring the need for improved treatment options.
Novocure is also conducting the Phase 2 PANOVA-4 trial, which has completed enrollment and is exploring TTFields therapy in combination with atezolizumab, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer, with results expected in 2026.
This report is based on a press release statement from Novocure. Analyst price targets for the company range from $18 to $40, reflecting mixed opinions about the company's prospects. For comprehensive analysis and additional insights, including 8 more ProTips and detailed financial metrics, visit InvestingPro's exclusive research report.
In other recent news, NovoCure (NASDAQ:NVCR) has seen a flurry of significant developments. The company reported a 22% increase in net revenues for the third quarter, totaling $155 million, driven by an uptick in active patients and improved U.S. approval rates. The firm Evercore ISI has upgraded NovoCure to outperform, raising its price target to $30, following an in-depth analysis of the company's valuation.
In addition, NovoCure has received FDA approval for its Head Flexible Electrode (HFE) arrays, a noteworthy development for the Optune Gio® system used in glioblastoma multiforme (GBM) treatment. The lighter, thinner HFE arrays are expected to enhance patient comfort, with a rollout planned for U.S. users by the first half of 2025.
NovoCure also announced the FDA's approval of Optune Lua for the treatment of post-platinum metastatic non-small cell lung cancer (NSCLC), further shaping the company's trajectory. H.C. Wainwright has maintained a Buy rating for NovoCure following these robust third-quarter results.
Lastly, NovoCure revealed that CEO Asaf Danziger will retire by the end of 2024, with CFO Ashley Cordova set to assume the role. These are some of the recent developments that continue to shape NovoCure's trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.